Impumelelo entsha yonyango lomhlaza wemiphunga ngo-2020

Ngo-2020, kwenziwa inkqubela phambili ebalulekileyo kunyango lomhlaza wemiphunga, kubandakanywa nolwamkelo lonyango olutsha ekujoliswe kulo kunye ne-immunotherapies, ebonelela ngeziphumo eziphuculweyo kunye neendlela zomntu ngamnye kwizigulana. Ezi mpumelelo zibonelele ngokhetho olutsha kwabo balwa nomhlaza wemiphunga, bajongana neenguqu ezithile zemfuzo kunye nokwandisa impendulo yomzimba yokulwa nesifo.Unyaka weNkqubela: Isitshixo Impumelelo eNtsha yoNyango loMhlaza wama-2020Unyaka ka-2020 uphawule unyaka obalulekileyo kumlo ochasene nomhlaza wemiphunga. Ngelixa unyaka ubulawulwa ngubhubhane wehlabathi, abaphandi kunye noogqirha baqhubekile nokutyhala imida yokhetho lonyango. Uphuhliso oluninzi oluthembisayo luye lwavela, lunika ithemba kwizigulana kunye nokuhlengahlengisa imeko yokhathalelo lomhlaza wemiphunga. I-Shandong Baofa Cancer Research Institute iye yalandela le nkqubela phambili ngokusondeleyo.Unyango olujoliswe kuyo: Precision Medicine Advances Unyango olujoliswe kuyo, olwenzelwe ukuhlasela ubuthathaka obuthile kwiiseli zomhlaza, lwabona inkqubela phambili ephawulekayo ngo-2020. Olu nyango luhlala lukhokelela kwimiphumo emibi embalwa kune-chemotherapy yendabuko kuba ijolise kwiiseli zomhlaza ngokuchanekileyo. umhlaza wemiphunga yeseli (NSCLC). Ngo-2020, ii-EGFR inhibitors ezintsha neziphuculweyo zavunywa, zibonelela ngenkqubela phambili-simahla yokusinda kwizigulana ezinolu tshintsho. Ezi zithinteli zesizukulwana esitsha zihlala zoyisa iindlela zokuxhathisa ezinciphisa ukusebenza kwamachiza angaphambili. Ngokukodwa, iiarhente ezijolise kwi-EGFR i-exon 20 yokuguqulwa kweenguqu zibonise umsebenzi othembisayo.Umzekelo, enye i-arhente i-amivantamab. Le theyibhile ilandelayo ibonisa iziphumo zolingo lwezonyango lwe-amivantamab: IsiGaba soLingo siSixa seMpendulo iyonke (ORR) Ubude bexesha lokuPhendula (DoR) iSigaba I-40% 11.1 iinyanga Umthombo: I-FDAI-ALK Inhibitors: Ukwandisa ii-Treatment OptionsI-Anaplastic lymphoma kinase (ALK) ukulungiswa kwakhona yenye ukuguqulwa komqhubi kwi-NSCLC. Uninzi lwe-ALK inhibitors sele lukhona, kwaye ngo-2020, uphando lugxile ekoyiseni ukuchasana nala machiza kunye nokuphuhlisa ii-inhibitors ezinamandla ngakumbi. Unyango olutsha oludityanisiweyo luphinde lwaphononongwa ukuphucula iziphumo kwi-ALK-positive lung cancer.Immunotherapy: Ukuhlanganisa Amandla e-Immune SystemImmunotherapy, eyonyusa amajoni omzimba ukulwa nomhlaza, iqhubekile ibe yindawo enkulu yenkqubela phambili kunyango lomhlaza wemiphunga ngo-2020.I-Checkpoint Inhibitors kwi-Earlier StagesCheckpoint, i-zumab inhibitors kunye ne-petroli-inhibitor yaguqula unyango lomhlaza wemiphunga ophezulu. Ngo-2020, izifundo zaphonononga ukusetyenziswa kwala machiza kumanqanaba angaphambili esi sifo, kubandakanya emva kotyando okanye zidityaniswe nechemotherapy. Ezi zifundo zibonise ukuba unyango lwe-immunotherapy lunokuphucula amazinga okuphila kunye nokunciphisa umngcipheko wokuphindaphinda kwezinye izigulane.I-Combination Immunotherapy Regimens Abaphandi baye baphanda ukudibanisa amachiza ahlukeneyo onyango ukuze kuphuculwe ukusebenza kwawo. I-blockade yokuhlola kabini, isebenzisa iindidi ezimbini ezahlukeneyo ze-immune checkpoint inhibitors, ibonise isithembiso kwezinye izigulane ezingazange ziphendule kwi-agent-agent immunotherapy. Ulingo lwezonyango luqhubekile nokucokisa ezi ndlela zokudibanisa ukuchonga izigulane ezinokuthi zixhamle.Indima yoVavanyo lwe-BiomarkerUkuqhubela phambili kunyango olujoliswe kuyo kunye ne-immunotherapies lubonise ukubaluleka kovavanyo olubanzi lwe-biomarker kumhlaza wemiphunga. Ngo-2020, kukho ugxininiso olwandisiweyo ekuvavanyeni uluhlu olubanzi lweenguqu zofuzo kunye ne-PD-L1 intetho yokukhokela izigqibo zonyango. Le ndlela yokwenziwa komntu ngamnye iqinisekisa ukuba izigulane zifumana olona nyango lufanelekileyo nolusebenzayo kumhlaza wabo othile.IZiko loPhando ngoMhlaza iShandong Baofa ligxininisa ukubaluleka kovavanyo olubanzi ukuze kuphunyezwe ezona ziphumo zingcono.Ukukhangela Phambili: Izikhokelo zexesha elizayo Impumelelo entsha yonyango lomhlaza wemiphunga ngo-2020 yavula indlela yenkqubela phambili engakumbi kwiminyaka ezayo. Uphando oluqhubekayo lujolise ekuphuhliseni unyango olutsha olujoliswe kuyo, ukuphucula izicwangciso ze-immunotherapy, kunye nokuchonga i-biomarkers inoveli. Eyona njongo iphambili kukuphuhlisa unyango olusebenzayo ngakumbi nolwenzelwe wena oluphucula amazinga okusinda kunye nomgangatho wobomi kuzo zonke izigulana ezinomhlaza wemiphunga. Ukuvunywa kweendlela ezintsha zonyango ezijoliswe kuzo kunye ne-immunotherapies, kunye nogxininiso olwandisiweyo kuvavanyo lwe-biomarker, luyiguqule imbonakalo yomhlaba yokhathalelo lomhlaza wemiphunga. Oku kuphumelela kunika ithemba kwizigulane kunye neentsapho zabo kwaye kugxininise ukubaluleka kophando oluqhubekayo kunye nokutsha ekulweni nesi sifo esiyingozi. Cinga ngokundwendwela IZiko loPhando loMhlaza laseShandong Baofa website ngolwazi oluthe kratya malunga nolingo lwezonyango kunye nonyango oluphambili lomhlaza.